{"id":1516,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-09-13","marketCap":1971.2347412109375,"name":"SpringWorks Therapeutics Inc","phone":"12038839490.0","outstanding":62.58000183105469,"symbol":"SWTX","website":"https://www.springworkstx.com/","industry":"Biotechnology"},"price":31.0925,"year":2023,"month":12,"day":9,"weekday":"Saturday","title":"Challenges and Opportunities for Investors in SpringWorks Therapeutics Inc Stock","date":"2023-12-09","url":"/posts/2023/12/09/SWTX","content":[{"section":"1. Biotech Industry Volatility","text":"One challenge for investors in SpringWorks Therapeutics Inc stock is the inherent volatility of the biotech industry. Biotech stocks are highly sensitive to factors such as clinical trial results, regulatory approvals, and market sentiment. This volatility can lead to significant fluctuations in the stock price, making it important for investors to carefully assess the company's pipeline, partnerships, and market potential."},{"section":"2. Clinical Development and Regulatory Risks","text":"Investing in a biotech company like SpringWorks Therapeutics Inc involves significant clinical development and regulatory risks. The success of the company's pipeline drugs heavily relies on positive clinical trial results and subsequent regulatory approvals. Investors should closely monitor the progress of these trials and the company's ability to meet regulatory requirements, as any setbacks or delays can impact the stock price."},{"section":"3. Pipeline Diversity and Potential","text":"One opportunity for investors in SpringWorks Therapeutics Inc is the diversity and potential of its pipeline. The company focuses on developing targeted therapies for rare diseases and cancer, with multiple candidates in different stages of development. Having a diversified pipeline can reduce the risk associated with relying on a single drug's success and increase the potential for future revenue streams."},{"section":"4. Strategic Partnerships and Collaborations","text":"SpringWorks Therapeutics Inc has established strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. These partnerships can provide opportunities for shared resources, expertise, and funding. Investors should evaluate the strength and potential benefits of these collaborations when considering an investment in the company."},{"section":"5. Market Potential and Competitive Landscape","text":"Assessing the market potential and competitive landscape is crucial for investors. Evaluating the size of the target market, the demand for the company's therapies, and competition from existing or upcoming treatments can provide insights into the revenue potential and sustainability of the company's business. Investors should carefully analyze market dynamics and the competitive advantage of SpringWorks Therapeutics Inc in order to make informed investment decisions."},{"section":"6. Financial Performance and Funding","text":"Investors should also consider the financial performance and funding of SpringWorks Therapeutics Inc. Analyzing the company's revenue growth, cash flow, and ability to secure funding for research and development activities are important factors for assessing its long-term prospects. Investors should closely monitor the company's financial statements, SEC filings, and news releases to stay informed about its financial health and sustainability."},{"section":"7. Regulatory Environment and Policy Changes","text":"Changes in the regulatory environment, such as modifications to drug approval processes or pricing regulations, can significantly impact biotech companies like SpringWorks Therapeutics Inc. Investors should stay abreast of regulatory developments and assess the potential impact on the company's operations and profitability. Monitoring policy changes related to healthcare and pharmaceutical industries can provide insights into potential risks and opportunities for investors."},{"section":"8. Long-Term Growth Potential","text":"Investing in SpringWorks Therapeutics Inc stock requires considering its long-term growth potential. Assessing the company's ability to successfully develop and commercialize its pipeline drugs, sustain revenue growth, and expand into new markets is essential for long-term investors. Evaluating the management team, their track record, and strategic vision can provide insights into the company's growth prospects."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702069500,"headline":"SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares","id":124406138,"image":"https://media.zenfs.com/en/globenewswire.com/1d76a773b101d90fe2cf67cbb32c7cff","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-closing-upsized-210500925.html"},{"category":"company","date":1701777600,"headline":"Celebrating Seeking Alpha's New Analysts - November 2023 Edition","id":124305651,"image":"https://static.seekingalpha.com/uploads/2023/11/3/saupload_eHacq8EQ.png","symbol":"SWTX","publisher":"SeekingAlpha","summary":"Discover new voices and perspectives in the financial world with Seeking Alpha's November edition of their monthly series highlighting new analysts.","url":"https://seekingalpha.com/article/4655803-celebrating-seeking-alphas-new-analysts-november-2023-edition"},{"category":"company","date":1701765900,"headline":"Biggest stock movers today: CVS Health, NIO, Ericsson, Nokia and more","id":124304025,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242231710"},{"category":"company","date":1701759240,"headline":"Biggest stock movers today: NIO, GitLab, Ericsson, Nokia and more","id":124304037,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242103604"},{"category":"company","date":1701754980,"headline":"SpringWorks Therapeutics 9.483M share Spot Secondary priced at $29.00","id":124314321,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242036316"},{"category":"company","date":1701754320,"headline":"SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","id":124315710,"image":"https://media.zenfs.com/en/globenewswire.com/0c953b5be9deaabd053f64d7a0ae1d9d","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being sold by SpringWorks. The gross proceeds from the offering, before deducting underwriting discounts and commissions and","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-pricing-upsized-053200044.html"},{"category":"company","date":1701752820,"headline":"SpringWorks announces pricing of upsized public offering of common stock","id":124314322,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242006544"},{"category":"company","date":1701749640,"headline":"Biggest stock movers today: GitLab, Ericsson, Nokia and more","id":124304057,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241963849"},{"category":"company","date":1701724380,"headline":"SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock","id":124293592,"image":"https://media.zenfs.com/en/globenewswire.com/0c953b5be9deaabd053f64d7a0ae1d9d","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-proposed-public-211300584.html"},{"category":"company","date":1701668400,"headline":"Fly Intel: After-Hours Movers","id":124293349,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241233752"},{"category":"company","date":1701660180,"headline":"SpringWorks Therapeutics $250M Spot Secondary; price range $28.80-$30.00","id":124293352,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241026138"},{"category":"company","date":1701660180,"headline":"SpringWorks Therapeutics $250M  price range $28.80-$30.00","id":124293351,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241026136"},{"category":"company","date":1701659700,"headline":"SpringWorks Therapeutics announces $250M common stock offering","id":124293354,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241015736"},{"category":"company","date":1701427643,"headline":"SpringWorks: Springing Forward On FDA Approval, Right Into Overpriced Territory","id":124225250,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/113708850/image_113708850.jpg?io=getty-c-w1536","symbol":"SWTX","publisher":"SeekingAlpha","summary":"SpringWorks Therapeutics has made a lot of waves in recent days following their first drug approval in non-cancerous desmoid tumors. Explore more details here.","url":"https://seekingalpha.com/article/4655418-springworks-stock-springing-forward-fda-approval-overpriced-territory"},{"category":"company","date":1701424620,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124226086,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3237044638"},{"category":"company","date":1701412020,"headline":"Strong Buy: Springworks Therapeutics’ Ogsiveo Poised for Market Success","id":124236251,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3236814856"},{"category":"company","date":1701346740,"headline":"Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session","id":124204725,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235382648"},{"category":"company","date":1701344280,"headline":"RDHL, VIEW and PIXY among mid-day movers","id":124204108,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235319930"},{"category":"company","date":1701335880,"headline":"La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday","id":124199397,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3235121542"},{"category":"company","date":1701259200,"headline":"SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference","id":124180153,"image":"https://media.zenfs.com/en/globenewswire.com/0c953b5be9deaabd053f64d7a0ae1d9d","symbol":"SWTX","publisher":"Yahoo","summary":"STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference, taking place in Miami, Florida on Thursday, November 30, 2023 at 8:45 a.m. ET. To access the live webcast please visit the Events \u0026 Presentations page within the Investors \u0026 Media section of","url":"https://finance.yahoo.com/news/springworks-therapeutics-participate-6th-annual-120000544.html"},{"category":"company","date":1701241560,"headline":"Analyst Ratings for SpringWorks Therapeutics","id":124175058,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3233110295"},{"category":"company","date":1701234840,"headline":"SpringWorks Therapeutics price target raised to $73 from $64 at H.C. Wainwright","id":124175060,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3233000911"},{"category":"company","date":1701205386,"headline":"SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment","id":124157357,"image":"https://media.zenfs.com/en/ibd.com/4dcd5df8aa61daca52a48bd0a7dc9cee","symbol":"SWTX","publisher":"Yahoo","summary":"SWTX stock soared Tuesday after U.S. regulators signed off on SpringWorks Therapeutics' new cancer treatment for desmoid tumors, Ogsiveo.","url":"https://finance.yahoo.com/m/a0c84f9a-eb97-30e5-8311-8474fcba0b99/springworks-catapults-19%25-on.html"},{"category":"company","date":1701195064,"headline":"SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear","id":124153649,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1152774435/image_1152774435.jpg?io=getty-c-w1536","symbol":"SWTX","publisher":"SeekingAlpha","summary":"SpringWorks Therapeutics received FDA approval for Ogsiveo, its treatment for adult patients with desmoid tumors. Click here to read an analysis of SWTX stock.","url":"https://seekingalpha.com/article/4654711-springworks-therapeutics-surging-on-ogsiveo-approval-long-term-outlook-remains-unclear"},{"category":"company","date":1701184298,"headline":"SpringWorks' non-cancerous tumor drug to be priced at $29,000 per month in US","id":124146160,"image":"","symbol":"SWTX","publisher":"Reuters","summary":"SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday.","url":"https://www.reuters.com/article/health-usa-tumor-springworks-1/springworks-non-cancerous-tumor-drug-to-be-priced-at-29000-per-month-in-us-idUSKBN32N12S"},{"category":"company","date":1701179684,"headline":"SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US  ","id":124146162,"image":"","symbol":"SWTX","publisher":"Reuters","summary":"SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday.","url":"https://www.reuters.com/article/health-usa-tumor-springworks/springworks-non-cancerous-tumor-drug-to-be-priced-at-29000-per-month-in-us-idUSL4N3CT30F"},{"category":"company","date":1701175800,"headline":"What You Missed On Wall Street This Morning","id":124148614,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231812996"},{"category":"company","date":1701175800,"headline":"Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Springworks Therapeutics (SWTX)","id":124148613,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231813047"},{"category":"company","date":1701173880,"headline":"PESI, AREN and CDIO among mid-day movers","id":124147787,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231769932"},{"category":"company","date":1701173160,"headline":"Carlyle Group, Seadrill rise; PG\u0026E, Argenx fall, Tuesday, 11/28/2023","id":124151766,"image":"","symbol":"SWTX","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=i86io2o181"},{"category":"company","date":1701171360,"headline":"12 Health Care Stocks Moving In Tuesday's Intraday Session","id":124147912,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231714809"},{"category":"company","date":1701168180,"headline":"SpringWorks Therapeutics (SWTX) Shares Cross Above 200 DMA","id":124148619,"image":"","symbol":"SWTX","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231644424"},{"category":"company","date":1701166380,"headline":"SpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors","id":124148620,"image":"","symbol":"SWTX","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231605924"},{"category":"company","date":1701161684,"headline":"SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US","id":124140099,"image":"","symbol":"SWTX","publisher":"Finnhub","summary":"SpringWorks Therapeutics'drug for treating adult patients with a type of rarenon-cancerous soft-tissue tumor will be sold in the U.S. at alist price of $29,000 for a 30-day supply, the company said...","url":"https://finnhub.io/api/news?id=c2a515d12d036f9a34cebc4d00215ad9f81b04061e55f83dd104a92d360d7941"},{"category":"company","date":1701161520,"headline":"Biggest stock movers today: Micron, PDD Holdings, Carlyle Group, Zscaler and more","id":124142777,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231507077"},{"category":"company","date":1701161160,"headline":"Buy Rating Affirmed for Springworks Therapeutics on OGSIVEO’s Superior Efficacy and FDA Approval","id":124148622,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231501243"},{"category":"company","date":1701160860,"headline":"PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday","id":124143723,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231494001"},{"category":"company","date":1701160440,"headline":"SpringWorks Therapeutics price target raised to $64 from $52 at H.C. Wainwright","id":124148624,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231486473"},{"category":"company","date":1701158100,"headline":"Fly Intel: Pre-market Movers","id":124148625,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231440334"},{"category":"company","date":1701157620,"headline":"SpringWorks Therapeutics’ stock jumps after FDA approves first treatment for rare type of aggressive tumors","id":124148627,"image":"","symbol":"SWTX","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231431576"},{"category":"company","date":1701157142,"headline":"SpringWorks Shares Rise on FDA Approval for Tumor Treatment","id":124138980,"image":"","symbol":"SWTX","publisher":"Finnhub","summary":"By Dean Seal Shares of SpringWorks were higher after the company received regulatory approval for its treatment of desmoid tumors. The stock was up 11% at $23.01 in premarket trading....","url":"https://finnhub.io/api/news?id=96024a7a92c4c565393a7410a086388de071ad27129155d1c7142cf2fb434629"},{"category":"company","date":1701156720,"headline":"Biggest stock movers today: PDD Holdings, Carlyle Group, Zscaler and more","id":124142778,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231415280"},{"category":"company","date":1701155040,"headline":"Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket","id":124143272,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231386330"},{"category":"company","date":1701154907,"headline":"First pill for desmoid tumours approved","id":124138242,"image":"","symbol":"SWTX","publisher":"Finnhub","summary":"The US Food and Drug Administration has approved the first drug for desmoid tumours , an oral gamma secretase inhibitor. SpringWorks Therapeutics' Ogsiveo tabl...","url":"https://finnhub.io/api/news?id=596d80deb7b49cbba7fce6d405d5498dc90224d29e76158e852ec27499a5aed5"},{"category":"company","date":1701151620,"headline":"Buy Rating on Springworks Therapeutics with Increased Price Target Following FDA Approval of Ogsiveo","id":124175063,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3232269043"},{"category":"company","date":1701151620,"headline":"SpringWorks Therapeutics price target raised to $50 from $45 at BofA","id":124175062,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3232269042"},{"category":"company","date":1701146100,"headline":"SpringWorks Therapeutics price target raised to $52 from $47 at Goldman Sachs","id":124175065,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3232130149"},{"category":"company","date":1701142140,"headline":"What You Missed On Wall Street On Tuesday","id":124151588,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3232030487"},{"category":"company","date":1701136260,"headline":"Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session","id":124149208,"image":"","symbol":"SWTX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231895604"},{"category":"company","date":1701134580,"headline":"SpringWorks to charge $29K/month for newly approved drug: report","id":124148631,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3231856417"},{"category":"company","date":1701127551,"headline":"US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment","id":124133264,"image":"https://static.reuters.com/resources/r/?m=02\u0026d=20231127\u0026t=2\u0026i=1652430315\u0026r=LYNXMPEJAQ0T7","symbol":"SWTX","publisher":"Reuters","summary":"The U.S. health regulator on Monday approved SpringWorks Therapeutics' drug for treating adult patients with desmoid tumors, making it the first approved treatment for this type of non-cancerous soft-tissue growth.","url":"https://www.reuters.com/article/health-usa-tumor-springworks/us-fda-approves-springworks-therapeutics-non-cancerous-tumor-treatment-idUSKBN32M1PU"},{"category":"company","date":1701126240,"headline":"SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors","id":124135329,"image":"https://media.zenfs.com/en/globenewswire.com/0c953b5be9deaabd053f64d7a0ae1d9d","symbol":"SWTX","publisher":"Yahoo","summary":"– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – – SpringWorks to host conference call tomorrow at 8:00 a.m. ET – A Media Snippet accompanying this announcement is available by clicking on this link. STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX),","url":"https://finance.yahoo.com/news/springworks-therapeutics-announces-fda-approval-230400700.html"},{"category":"company","date":1701124842,"headline":"US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment ","id":124133265,"image":"","symbol":"SWTX","publisher":"Reuters","summary":"The U.S. Food and Drug Administration (FDA) on Monday approved SpringWorks Therapeutics' drug for treating a type of non-cancerous soft-tissue tumor in adults. (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)","url":"https://www.reuters.com/article/health-usa-tumor-springworks/us-fda-approves-springworks-therapeutics-non-cancerous-tumor-treatment-idUSL4N3CS3MR"},{"category":"company","date":1701109923,"headline":"SpringWorks Gets FDA Approval for Desmoid Tumor Treatment","id":124131904,"image":"","symbol":"SWTX","publisher":"Finnhub","summary":"By Ben Glickman SpringWorks Therapeutics has received approval from the Food and Drug Administration for its treatment of desmoid tumors. The Stamford, Conn.-based biopharmaceutical...","url":"https://finnhub.io/api/news?id=cf772488e92c77214efcbfd403e82f7d248b3dc4b5e2081c8edc15685110965d"},{"category":"company","date":1701063780,"headline":"SpringWorks stock rallies 18% post-market on FDA approval of Ogsiveo","id":124132270,"image":"","symbol":"SWTX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3230556602"},{"category":"company","date":1701062760,"headline":"Buy Rating for Springworks Therapeutics on Strong FDA Approval and Market Potential","id":124132271,"image":"","symbol":"SWTX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3230533973"},{"category":"company","date":1701061560,"headline":"SpringWorks Therapeutics announces FDA approval of OGSIVEO","id":124132272,"image":"","symbol":"SWTX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3230507081"}]}